Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31.

No abstract is available for this paper.

• Publication year

  1997

• Venue

  Journal of Clinical Oncology

• Publication date

  1997-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.1997.15.3.1013PMID 9060541
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radiation Therapy Oncology Group.

  1995cited by this paper
• Phase II trial of hormonal cytoreduction with megestrol and diethylstilbestrol in conjunction with radiotherapy for carcinoma of the prostate: outcome results of RTOG 83-07.

  1995cited by this paper
• Prognostic factors in stage D2 prostate cancer; important implications for future trials: results of a cooperative intergroup study (INT.0036). The National Cancer Institute Intergroup Study #0036.

  1994cited by this paper
• Hormonal treatment at time of radical retropubic prostatectomy for stage D1 prostate cancer: results of long-term followup.

  1992cited by this paper
• Phase II Radiation Therapy Oncology Group Study of Hormonal Cytoreduction with Flutamide and Zoladex in Locally Advanced Carcinoma of the Prostate Treated with Definitive Radiotherapy

  1990cited by this paper
• Prognosis of patients with stage D1 prostate carcinoma following radical prostatectomy with and without early endocrine therapy.

  1990cited by this paper
• A controlled trial of leuprolide with and without flutamide in prostatic carcinoma.

  1989cited by this paper
• Hormone therapy for prostate cancer: results of the Veterans Administration Cooperative Urological Research Group studies.

  1989cited by this paper
• Adjuvant estrogen following radiation therapy for stage C adenocarcinoma of the prostate: long-term results of a prospective randomized study.

  1988cited by this paper
• Radical Prostatectomy and the Influence of Early Endocrine Therapy for Stage D1 Prostate Cancer: Long-Term Follow-Up Study

  1988cited by this paper
• A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk

  1988cited by this paper
• Prognostic factors in carcinoma of the prostate--analysis of RTOG study 75-06.

  1987cited by this paper
• Hormonal cytoreduction in locally advanced carcinoma of the prostate treated with definitive radiotherapy: preliminary results of RTOG 83-07.

  1987cited by this paper
• The Statistical Analysis of Failure Time Data

  1980cited by this paper
• Long-term curative results of radiotherapy of patients with inoperable prostatic carcinoma. Erskine Memorial Lecture, 1978.

  1979cited by this paper
• Long-term curative results of radiotherapy of patients with inoperable prostatic carcinoma. Erskine Memorial Lecture, 1978.

  1979cited by this paper
• Megavoltage radiation therapy for carcinoma of the prostate.

  1977cited by this paper
• Localized advanced carcinoma of the prostate: radiation therapy versus hormonal therapy.

  1976cited by this paper
• The randomization and stratification of patients to clinical trials.

  1974cited by this paper
• Treatment of prostatic cancer: studies by the Veterans Administration cooperative urological research group.

  1972cited by this paper
• Treatment of prostatic cancer: studies by the Veterans Administration cooperative urological research group.

  1972cited by this paper
• Regression Models and Life-Tables

  1972cited by this paper
• Evaluation of survival data and two new rank order statistics arising in its consideration.

  1966cited by this paper
• Nonparametric Estimation from Incomplete Observations

  1958cited by this paper
• Endocrine control of prostatic carcinoma; clinical and statistical survey of 1,818 cases.

  1950cited by this paper
• Prostatic carcinoma; a follow-up on 795 patients treated prior to the endocrine era and a comparison of survival rates between these and patients treated by endocrine therapy.

  1946cited by this paper
• Prostatic carcinoma; a follow-up on 795 patients treated prior to the endocrine era and a comparison of survival rates between these and patients treated by endocrine therapy.

  1946cited by this paper
• STUDIES ON PROSTATIC CANCER: II. THE EFFECTS OF CASTRATION ON ADVANCED CARCINOMA OF THE PROSTATE GLAND

  1941cited by this paper
• Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate.

  1941cited by this paper

• Long term results of NRG Oncology RTOG 9601, a randomized trial of radiation with or without anti-androgens (AAT) in patients receiving salvage prostate bed radiation therapy post prostatectomy.

  2025cites this paper
• Hormonal Therapy Patterns in Older Men with Prostate Cancer in the United States, 2010–2019

  2025cites this paper
• Early change in apparent diffusion coefficient as a predictor of response to neoadjuvant androgen deprivation and external beam radiation therapy for intermediate- to high-risk prostate cancer.

  2024cites this paper
• Intensifying the Hormonal and Radiation Treatment in Prostate Cancer Presenting With Bulky Pelvic Lymph Nodes: An Opportunity for a New Paradigm

  2024cites this paper
• The Current Trend of Radiation Therapy for Patients with Localized Prostate Cancer

  2023cites this paper
• Neoadjuvant versus Concurrent Androgen Deprivation Therapy in Localized Prostate Cancer Treated with Radiotherapy: A Systematic Review of the Literature

  2023cites this paper
• How can we best manage biochemical failure after radical prostatectomy?

  2022cites this paper
• The Use of Androgen Deprivation Therapy in Combination With Radiation for Localized Prostate Cancer

  2022cites this paper
• Patient-reported Outcomes from a Phase III Randomized Controlled Trial Exploring Optimal Sequencing of Short-term Androgen Deprivation Therapy with Prostate Radiotherapy in Localized Prostate Cancer.

  2021cites this paper
• Radio-hormonothérapie des cancers de la prostate : quelle efficacité ? Quels mécanismes ?

  2021cites this paper
• Whole Pelvic Radiotherapy With Stereotactic Body Radiotherapy Boost vs. Conventionally Fractionated Radiotherapy for Patients With High or Very High-Risk Prostate Cancer

  2020cites this paper
• Radiation Therapy for Prostate Cancer.

  2020cites this paper
• The Impact of Geographic Location on Saskatchewan Prostate Cancer Patient Treatment Choices: A Multilevel and Spatial Analysis.

  2020cites this paper
• Current Approach in Radiation Therapy for Prostate Cancer

  2020cites this paper
• [Indications and outlooks of radiohormonal therapy of high-risk prostate cancers].

  2020cites this paper
• [Optimizing local control of high-risk prostate cancers through multimodal treatments].

  2019cites this paper
• Achieving PSA < 0.2 ng/ml before Radiation Therapy Is a Strong Predictor of Treatment Success in Patients with High-Risk Locally Advanced Prostate Cancer

  2019cites this paper
• Combining prostate cancer radiotherapy with therapies targeting the androgen receptor axis.

  2019cites this paper
• Sequencing of Androgen-Deprivation Therapy With External-Beam Radiotherapy in Localized Prostate Cancer: A Phase III Randomized Controlled Trial.

  2019influential citation
• The history of cancer screening.

  2019cites this paper
• DNA repair inhibitors to enhance radiotherapy: Progresses and limitations.

  2019cites this paper
• Prostate cancer.

  2019cites this paper
• Where Do We See Alpha Emitters in Clinical Practice? A Radiation Oncology Perspective.

  2019cites this paper
• Aspekte der Hormontherapie des Prostatakarzinoms

  2019cites this paper
• Evaluation of overall survival rate of different therapies in the treatment of T1-T3 prostate cancer: a network meta-analysis.

  2018cites this paper
• Neoadjuvant and adjuvant treatment in high-risk prostate cancer

  2018cites this paper
• Towards a personalised medicine strategy to reduce prostate cancer risk in men

  2018cites this paper
• Are all gonadotrophin‐releasing hormone agonists equivalent for the treatment of prostate cancer? A systematic review

  2018cites this paper
• Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017.

  2018cites this paper
• The impact of the definition of biochemical recurrence following salvage radiotherapy on outcomes and prognostication in patients with recurrent prostate cancer after radical prostatectomy: a comparative study of three definitions

  2018cites this paper
• Prostate cancer screening: And the pendulum swings

  2018cites this paper
• Bestrahlung mit zusätzlicher Antiandrogentherapie

  2018cites this paper
• Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921.

  2018cites this paper
• Androgen Deprivation Therapy and Dose-Escalated Radiotherapy for Intermediate- and High-Risk Prostate Cancer-Reply.

  2017cites this paper
• High‐Risk Prostate Cancer and Radiotherapy: The Past and the Future. A Benchmark for a New Mixed Beam Radiotherapy Approach

  2017cites this paper
• Prostate Cancer Screening.

  2017cites this paper
• Title Management of Patients with Advanced Prostate Cancer : The Report of the Advanced Prostate Cancer

  2017cites this paper
• [Radiation with additional antiandrogen therapy in recurrent prostate cancer].

  2017cites this paper
• Cancer Screening and Early Detection

  2017cites this paper
• Weighing Risk of Cardiovascular Mortality Against Potential Benefit of Hormonal Therapy in Intermediate-Risk Prostate Cancer

  2017cites this paper
• Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer

  2017cites this paper
• Beobachtungsstudie bei Mamma- und Bronchialkarzinomen

  2017cites this paper
• Risk of Death from Prostate Cancer with and without Definitive Local Therapy when Gleason Pattern 5 is Present: A Surveillance, Epidemiology, and End Results Analysis

  2017cites this paper
• Network meta-analysis of the efficacy and adverse effects of several treatments for advanced/metastatic prostate cancer

  2017cites this paper
• Multimodal therapy for locally advanced prostate cancer: the roles of radiotherapy, androgen deprivation therapy, and their combination

  2017influential citation
• Bestrahlung mit zusätzlicher Antiandrogentherapie beim Prostatakarzinomrezidiv

  2017cites this paper
• Interfractional Seminal Vesicle Motion Relative to the Prostate Gland for Image-guided Radiotherapy for Prostate Cancer with/without Androgen Deprivation Therapy: A Retrospective Cohort Study.

  2017cites this paper
• Evolving Recommendations on Prostate Cancer Screening.

  2016cites this paper
• Radiation with Hormonal Therapy

  2016cites this paper
• Cardiovascular Mortality Following Short-term Androgen Deprivation in Clinically Localized Prostate Cancer: An Analysis of RTOG 94-08.

  2016cites this paper
• CLINICAL OUTCOMES OF EXTERNAL-BEAM RADIOTHERAPY COMBINED WITH NEOADJUVANT ANDROGEN DEPRIVATION THERAPY FOR HIGH-RISK PROSTATE CANCER.

  2016cites this paper
• Assessment of the Rate of Adherence to International Guidelines for Androgen Deprivation Therapy with External-beam Radiation Therapy: A Population-based Study.

  2016cites this paper
• Evolving Paradigm of Radiotherapy for High-Risk Prostate Cancer: Current Consensus and Continuing Controversies

  2016cites this paper
• Comparative effectiveness of radical prostatectomy and curative radiotherapy in localized prostate cancer: long-term follow-up

  2016cites this paper
• Students With Protected Disability Status by Type Students by Protected Disability Status

  2016cites this paper
• The role of androgen deprivation therapy plus radiation therapy in patients with non-metastatic prostate cancer

  2016cites this paper
• Chapter 143 – Endocrinology of Benign Prostatic Hyperplasia and Prostate Cancer

  2016cites this paper
• Radiotherapy before and after radical prostatectomy for high-risk and locally advanced prostate cancer.

  2015cites this paper
• Co nowego w leczeniu napromienianiem raka stercza oraz raka pęcherza moczowego na podstawie doniesień z Konferencji Amerykańskiego Towarzystwa Radioterapii Onkologicznej (ASTRO), San Francisco 2014?

  2015cites this paper
• Radiotherapy for high-risk prostate cancer

  2015cites this paper
• Systematic Review and Meta-analysis of the Survival Outcomes of First-line Treatment Options in High-risk Prostate Cancer

  2015cites this paper
• Clinical Significance of Neoadjuvant Combined Androgen Blockade for More Than Six Months in Patients with Localized Prostate Cancer Treated with Prostate Brachytherapy

  2015cites this paper
• Pharmacologic androgen deprivation and cardiovascular disease risk factors: a systematic review

  2015cites this paper
• Patterns of Declining Use and the Adverse Effect of Primary Androgen Deprivation on All-cause Mortality in Elderly Men with Prostate Cancer.

  2015cites this paper
• Contribution of Chemotherapy to the Toxicity of Pelvic Irradiation

  2015cites this paper
• Combination of androgen deprivation therapy and radiotherapy for localized prostate cancer in the contemporary era.

  2015cites this paper
• External Beam Radiation Therapy and Abiraterone in Men With Localized Prostate Cancer: Safety and Effect on Tissue Androgens

  2015cites this paper
• In Reply to Bhattacharyya et al.

  2015cites this paper
• Hormone therapy in combination with radiotherapy in the treatment of prostate cancer: why and in which group of patients?

  2015cites this paper
• Comparison of primary radiation versus robotic surgery plus adjuvant radiation in high-risk prostate cancer: a single center experience.

  2015cites this paper
• Salvage reirradiation for locoregional failure after radiation therapy for prostate cancer: Who, when, where and how? Modalités des réirradiations de rattrapage pour les rechutes locales des cancers de la prostate

  2014cites this paper
• Efficacy and toxicity of external-beam radiation therapy for localised prostate cancer: a network meta-analysis

  2014cites this paper
• Differences in time to disease progression do not predict for cancer-specific survival in patients receiving immediate or deferred androgen-deprivation therapy for prostate cancer: final results of EORTC randomized trial 30891 with 12 years of follow-up.

  2014cites this paper
• Salvage reirradiation for locoregional failure after radiation therapy for prostate cancer: who, when, where and how?

  2014cites this paper
• Treatment strategies for locally advanced prostate cancer.

  2014cites this paper
• Is intermittent androgen‐deprivation therapy beneficial for patients with advanced prostate cancer?

  2014cites this paper
• A Comprehensive Review of Contemporary Role of Local Treatment of the Primary Tumor and/or the Metastases in Metastatic Prostate Cancer

  2014cites this paper
• Management of Patients with Prostate Cancer

  2014cites this paper
• Adjuvant leuprolide with or without docetaxel in patients with high‐risk prostate cancer after radical prostatectomy (TAX‐3501)

  2013cites this paper
• Guideline-discordant androgen deprivation therapy in localized prostate cancer: patterns of use in the medicare population and cost implications.

  2013cites this paper
• Androgen deprivation therapy and acute kidney injury.

  2013cites this paper
• Treatment of prostate cancer with intermittent versus continuous androgen deprivation: a systematic review of randomized trials.

  2013cites this paper
• Soy protein and recurrence of prostate cancer.

  2013cites this paper
• IS THE REAL PRACTICE OF ANDROGEN DEPRIVATION THERAPY MONOTHERAPY IN LOCALLY ADVANCED NONMETASTATIC DISEASE SO LIMITED

  2013cites this paper
• Future prospects: who is the patient who still dies of prostate cancer following local treatment of high-risk prostate cancer? Can we prolong their lives using modern treatment approaches?

  2013cites this paper
• Management of high-risk prostate cancer: radiation therapy and hormonal therapy.

  2013cites this paper
• 高精度放射線治療の現状とAdaptive Therapyの展望：前立腺がんに対する放射線治療を中心に

  2013cites this paper
• Vaginal approaches to pelvic organ prolapse repair

  2013cites this paper
• Health Outcomes Research Prevalence of Patients With Nonmetastatic Prostate Cancer on Androgen Deprivation Therapy in the United States

  2013cites this paper
• Does comorbidity influence the risk of myocardial infarction or diabetes during androgen-deprivation therapy for prostate cancer?

  2013cites this paper
• Radiotherapy plus hormonal therapy

  2013cites this paper
• Nasty or Nice? Findings from a UK Survey to evaluate the impact of the National Institute for Health and Clinical Excellence (NICE) clinical guidelines on the management of prostate cancer.

  2013cites this paper
• Early salvage hormonal therapy for biochemical failure improved survival in prostate cancer patients after neoadjuvant hormonal therapy plus radiation therapy--a secondary analysis of irish clinical oncology research group 97-01.

  2013cites this paper
• Results of hormone therapy as first-line treatment for high-risk prostate cancer

  2013cites this paper
• Age Dependent Analysis and Modeling of Prostate Cancer Data

  2013cites this paper
• Treatment of high risk prostate cancer with combined radiotherapy and hormonal treatment- results and identification of factors influencing outcome.

  2013cites this paper
• Guidelines on Prostate Cancer

  2013cites this paper
• Current role of neoadjuvant and adjuvant systemic therapy for high-risk localized prostate cancer

  2013cites this paper
• Prevalence of patients with nonmetastatic prostate cancer on androgen deprivation therapy in the United States.

  2013cites this paper
• Death from high‐risk prostate cancer versus cardiovascular mortality with hormonal therapy

  2013cites this paper